1. Home
  2. BBIO vs VNT Comparison

BBIO vs VNT Comparison

Compare BBIO & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • VNT
  • Stock Information
  • Founded
  • BBIO 2015
  • VNT 2019
  • Country
  • BBIO United States
  • VNT United States
  • Employees
  • BBIO N/A
  • VNT N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • VNT Industrial Machinery/Components
  • Sector
  • BBIO Health Care
  • VNT Industrials
  • Exchange
  • BBIO Nasdaq
  • VNT Nasdaq
  • Market Cap
  • BBIO 4.9B
  • VNT 5.3B
  • IPO Year
  • BBIO 2019
  • VNT N/A
  • Fundamental
  • Price
  • BBIO $23.24
  • VNT $38.31
  • Analyst Decision
  • BBIO Strong Buy
  • VNT Buy
  • Analyst Count
  • BBIO 13
  • VNT 8
  • Target Price
  • BBIO $46.92
  • VNT $43.71
  • AVG Volume (30 Days)
  • BBIO 1.7M
  • VNT 1.0M
  • Earning Date
  • BBIO 11-12-2024
  • VNT 10-31-2024
  • Dividend Yield
  • BBIO N/A
  • VNT 0.26%
  • EPS Growth
  • BBIO N/A
  • VNT 21.70
  • EPS
  • BBIO N/A
  • VNT 2.62
  • Revenue
  • BBIO $217,765,000.00
  • VNT $2,991,200,000.00
  • Revenue This Year
  • BBIO $3,690.39
  • VNT N/A
  • Revenue Next Year
  • BBIO N/A
  • VNT $3.54
  • P/E Ratio
  • BBIO N/A
  • VNT $14.27
  • Revenue Growth
  • BBIO 2209.77
  • VNT N/A
  • 52 Week Low
  • BBIO $21.62
  • VNT $31.22
  • 52 Week High
  • BBIO $44.32
  • VNT $45.62
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 41.84
  • VNT 57.97
  • Support Level
  • BBIO $21.72
  • VNT $36.71
  • Resistance Level
  • BBIO $27.57
  • VNT $40.99
  • Average True Range (ATR)
  • BBIO 1.42
  • VNT 0.91
  • MACD
  • BBIO -0.23
  • VNT -0.24
  • Stochastic Oscillator
  • BBIO 25.98
  • VNT 39.91

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About VNT Vontier Corporation

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2023.

Share on Social Networks: